U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry MIXED
Molecular Formula C19H26I3N3O9
Molecular Weight 821.1386
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IOHEXOL

SMILES

CC(=O)N(CC(CO)O)c1c(c(c(c(c1I)C(=NCC(CO)O)O)I)C(=NCC(CO)O)O)I

InChI

InChIKey=NTHXOOBQLCIOLC-UHFFFAOYSA-N
InChI=1S/C19H26I3N3O9/c1-8(29)25(4-11(32)7-28)17-15(21)12(18(33)23-2-9(30)5-26)14(20)13(16(17)22)19(34)24-3-10(31)6-27/h9-11,26-28,30-32H,2-7H2,1H3,(H,23,33)(H,24,34)

HIDE SMILES / InChI

Description
Curator's Comment:: description was created based on several sources, including: http://www.drugbank.ca/drugs/DB01362 http://www.rxlist.com/omnipaque-drug.htm

Iohexol is a nonionic, water-soluble radiographic contrast medium. Organic iodine compounds block x-rays as they pass through the body, thereby allowing body structures containing iodine to be delineated in contrast to those structures that do not contain iodine. It is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Drugs which lower seizure threshold, especially phenothiazine derivatives including those used for their antihistaminic or antinauseant properties, are not recommended for use with Iohexol. Others include monoamine oxidase (MAO) inhibitors, tricyclic antidepressants, CNS stimulants, psychoactive drugs described as analeptics, major tranquilizers, or antipsychotic drugs. The most frequently reported adverse reactions are headache, mild to moderate pain including backache, neckache and stiffness, nausea, and vomiting.

CNS Activity

Curator's Comment:: Animal studies indicate that iohexol does not cross an intact blood-brain barrier to any significant extent following intravascular administration. http://www.ncbi.nlm.nih.gov/pubmed/2917821

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
OMNIPAQUE 300

Approved Use

—Intrathecal OMNIPAQUE 300 is indicated for intrathecal administration in adults including myelography (lumbar, thoracic, cervical, total columnar) and in contrast enhancement for computerized tomography (myelography, cisternography, ventriculography)., INDICATIONS AND USAGE, GENERAL—Intravascular OMNIPAQUE 350 is indicated in adults for angiocardiography (ventriculography, selective coronary arteriography), aortography including studies of the aortic root, aortic arch, ascending aorta, abdominal aorta and its branches, contrast enhancement for computed tomographic head and body imaging, intravenous digital subtraction angiography of the head, neck, abdominal, renal and peripheral vessels, peripheral arteriography, and excretory urography. OMNIPAQUE 350 is indicated in children for angiocardiography (ventriculography, pulmonary arteriography, and venography; studies of the collateral arteries and aortography, including the aortic root, aortic arch, ascending and descending aorta). OMNIPAQUE 300 is indicated in adults for aortography including studies of the aortic arch, abdominal aorta and its branches, contrast enhancement for computed tomographic head and body imaging, cerebral arteriography, peripheral venography (phlebography), and excretory urography. OMNIPAQUE 300 is indicated in children for angiocardiography (ventriculography), excretory urography, and contrast enhancement for computed tomographic head imaging., INDIVIDUAL INDICATIONS AND USAGE, INDICATIONS AND USAGE, GENERAL—Oral/Body Cavity Use OMNIPAQUE 300 and OMNIPAQUE 350 have osmolalities from approximately 1.6 to 3.0 times that of plasma (285 mOsm/kg water) and are hypertonic under conditions of use. Adults OMNIPAQUE 350 is indicated in adults for arthrography and oral pass-thru examination of the gastrointestinal tract. OMNIPAQUE 300 is indicated in adults for arthrography and hysterosalpingography. OMNIPAQUE diluted to concentrations from 6 mgI/mL to 9 mgI/mL administered orally in conjunction with OMNIPAQUE 300 at a concentration of 300 mgI/mL administered intravenously is indicated in adults for contrast enhanced computed tomography of the abdomen. Children OMNIPAQUE 300 is indicated in children for examination of the gastrointestinal tract. OMNIPAQUE diluted to concentrations from 50 mgI/mL to 100 mgI/mL is indicated in children for voiding cystourethrography. OMNIPAQUE diluted to concentrations from 9 mgI/mL to 21 mgI/mL administered orally in conjunction with OMNIPAQUE 300 at a concentration of 300 mgI/mL administered intravenously are indicated in children for use in contrast enhanced computed tomography of the abdomen., INDIVIDUAL INDICATIONS AND USAGE Oral Use Adults OMNIPAQUE 350 at a concentration of 350 mgI/mL is indicated in adults for use in oral pass-thru examination of the gastrointestinal tract. OMNIPAQUE diluted to concentrations from 6 mgI/mL to 9 mgI/mL administered orally in conjunction with OMNIPAQUE 300 at a concentration of 300 mgI/mL administered intravenously are indicated in adults for use in contrast enhanced computed tomography of the abdomen. Dilute oral plus intravenous OMNIPAQUE may be useful when unenhanced imaging does not provide sufficient delineation between normal loops of the bowel and adjacent organs or areas of suspected pathology. Children OMNIPAQUE 300 at a concentration of 300 mgI/mL administered orally or rectally is indicated in children for use in examination of the gastrointestinal tract. OMNIPAQUE diluted to concentrations from 9 mgI/mL to 21 mgI/mL administered orally in conjunction with OMNIPAQUE 300 at a concentration of 300 mgI/mL administered intravenously are indicated in children for use in contrast enhanced computed tomography of the abdomen. Precautions See PRECAUTIONS—General. Adverse Reactions Oral administration of OMNIPAQUE is most often associated with mild, transient diarrhea especially when high concentrations and large volumes are administered. Nausea, vomiting, and moderate diarrhea have also been reported following orally administered OMNIPAQUE, but much less frequently. For CT examinations using dilute oral plus intravenous contrast medium, adverse events are more likely to be associated with the intravenous injection than the hypotonic oral solution. It should be noted that serious or anaphylactoid reactions that may occur with intravascular iodinated media are possible following administration by other routes. Adults In controlled clinical trials involving 54 adult patients for oral pass-thru examination of the gastrointestinal tract using OMNIPAQUE 350, the following adverse reactions were reported: diarrhea (42%), nausea (15%), vomiting (11%), abdominal pain (7%), flatulence (2%), and headache (2%). In controlled clinical studies involving 44 adult patients for dilute oral plus intravenous CT examination of the gastrointestinal tract using OMNIPAQUE 300, adverse reactions were limited to a single report of vomiting (2%). Children In controlled clinical studies involving 58 pediatric patients for examination of the gastrointestinal tract at a concentration of 300 mgI/mL, the following adverse reactions were reported: diarrhea (36%), vomiting (9%), nausea (5%), fever (5%), hypotension (2%), abdominal pain (2%), and urticaria (2%). In clinical studies an increased frequency and severity of diarrhea was noted with an increase in the administered concentration and dose of the radiocontrast agent. In controlled clinical studies involving 69 pediatric patients for dilute oral plus intravenous CT examination of the gastrointestinal tract using OMNIPAQUE 300, adverse reactions were limited to a single report of vomiting (1.4%). Dosage and Administration Adults The recommended dosage of undiluted OMNIPAQUE 350 at a concentration of 350 mgI/mL for oral pass-thru examination of the gastrointestinal tract in adults is 50 mL to 100 mL depending on the nature of the examination and the size of the patient. The recommended oral dosage of OMNIPAQUE diluted to concentrations of 6 mgI/mL to 9 mgI/mL for contrast enhanced computed tomography of the abdomen in adults is 500 mL to 1000 mL. Smaller administered volumes are needed as the concentration of the final solution is increased (see Table below). In conjunction with dilute oral administration, the recommended dosage of OMNIPAQUE 300 administered intravenously is 100 mL to 150 mL. The oral dose is administered about 20 to 40 minutes prior to the intravenous dose and image acquisition. Children The dosage of undiluted OMNIPAQUE 300 at a concentration of 300 mgI/mL, is dependent on the nature of the examination and the size of the patient. Based on clinical experience, it is recommended that OMNIPAQUE 180 (available in single use vials), be used in children less than 3 months of age. OMNIPAQUE 300 may be used in children 3 months of age and older. The following dosage guidelines are recommended: Age Volume of OMNIPAQUE Less than 3 months 5 — 30 mL Three months to 3 years Up to 60 mL Four years to 10 years Up to 80 mL Greater than 10 years Up to 100 mL When given rectally, larger volumes may be used. The recommended oral dosage of OMNIPAQUE diluted to concentrations of 9 mgI/mL to 21 mgI/mL for contrast enhanced computed tomography of the abdomen in children is 180 mL to 750 mL. Smaller administered volumes are needed as the concentration of the final solution is increased (see Table below). The total oral dose in grams of iodine should generally not exceed 5 gI for children under 3 years of age and 10 gI for children from 3 to 18 years of age. The oral dosage may be given all at once or over a period of 30 to 45 minutes if there is difficulty in consuming the required volume. In conjunction with dilute oral administration the recommended dosage of OMNIPAQUE 300 is 2.0 mL/kg when administered intravenously with a range of 1.0 mL/kg to 2.0 mL/kg. Dosage for infants and children should be administered in proportion to age and body weight. The total intravenously administered dose should not exceed 3 mL/kg. The oral dose is administered about 30 to 60 minutes prior to the intravenous dose and image acquisition. OMNIPAQUE may be diluted with water or beverage as follows: Add To Stock Concentration of OMNIPAQUE (mgI/mL) Volume (mL) Water, Carbonated Beverage, Milk, or Juice (mL) 300 20 980 350 17 983 300 30 970 350 26 974 300 40 960 350 35 965 300 50 950 350 43 957 300 60 940 350 52 948 300 70 930 350 60 940 Dilutions of OMNIPAQUE should be prepared just prior to use and any unused portion discarded after the procedure.

Launch Date

5.04403198E11
Diagnostic
OMNIPAQUE 300

Approved Use

—Intrathecal OMNIPAQUE 300 is indicated for intrathecal administration in adults including myelography (lumbar, thoracic, cervical, total columnar) and in contrast enhancement for computerized tomography (myelography, cisternography, ventriculography)., INDICATIONS AND USAGE, GENERAL—Intravascular OMNIPAQUE 350 is indicated in adults for angiocardiography (ventriculography, selective coronary arteriography), aortography including studies of the aortic root, aortic arch, ascending aorta, abdominal aorta and its branches, contrast enhancement for computed tomographic head and body imaging, intravenous digital subtraction angiography of the head, neck, abdominal, renal and peripheral vessels, peripheral arteriography, and excretory urography. OMNIPAQUE 350 is indicated in children for angiocardiography (ventriculography, pulmonary arteriography, and venography; studies of the collateral arteries and aortography, including the aortic root, aortic arch, ascending and descending aorta). OMNIPAQUE 300 is indicated in adults for aortography including studies of the aortic arch, abdominal aorta and its branches, contrast enhancement for computed tomographic head and body imaging, cerebral arteriography, peripheral venography (phlebography), and excretory urography. OMNIPAQUE 300 is indicated in children for angiocardiography (ventriculography), excretory urography, and contrast enhancement for computed tomographic head imaging., INDIVIDUAL INDICATIONS AND USAGE, INDICATIONS AND USAGE, GENERAL—Oral/Body Cavity Use OMNIPAQUE 300 and OMNIPAQUE 350 have osmolalities from approximately 1.6 to 3.0 times that of plasma (285 mOsm/kg water) and are hypertonic under conditions of use. Adults OMNIPAQUE 350 is indicated in adults for arthrography and oral pass-thru examination of the gastrointestinal tract. OMNIPAQUE 300 is indicated in adults for arthrography and hysterosalpingography. OMNIPAQUE diluted to concentrations from 6 mgI/mL to 9 mgI/mL administered orally in conjunction with OMNIPAQUE 300 at a concentration of 300 mgI/mL administered intravenously is indicated in adults for contrast enhanced computed tomography of the abdomen. Children OMNIPAQUE 300 is indicated in children for examination of the gastrointestinal tract. OMNIPAQUE diluted to concentrations from 50 mgI/mL to 100 mgI/mL is indicated in children for voiding cystourethrography. OMNIPAQUE diluted to concentrations from 9 mgI/mL to 21 mgI/mL administered orally in conjunction with OMNIPAQUE 300 at a concentration of 300 mgI/mL administered intravenously are indicated in children for use in contrast enhanced computed tomography of the abdomen., INDIVIDUAL INDICATIONS AND USAGE Oral Use Adults OMNIPAQUE 350 at a concentration of 350 mgI/mL is indicated in adults for use in oral pass-thru examination of the gastrointestinal tract. OMNIPAQUE diluted to concentrations from 6 mgI/mL to 9 mgI/mL administered orally in conjunction with OMNIPAQUE 300 at a concentration of 300 mgI/mL administered intravenously are indicated in adults for use in contrast enhanced computed tomography of the abdomen. Dilute oral plus intravenous OMNIPAQUE may be useful when unenhanced imaging does not provide sufficient delineation between normal loops of the bowel and adjacent organs or areas of suspected pathology. Children OMNIPAQUE 300 at a concentration of 300 mgI/mL administered orally or rectally is indicated in children for use in examination of the gastrointestinal tract. OMNIPAQUE diluted to concentrations from 9 mgI/mL to 21 mgI/mL administered orally in conjunction with OMNIPAQUE 300 at a concentration of 300 mgI/mL administered intravenously are indicated in children for use in contrast enhanced computed tomography of the abdomen. Precautions See PRECAUTIONS—General. Adverse Reactions Oral administration of OMNIPAQUE is most often associated with mild, transient diarrhea especially when high concentrations and large volumes are administered. Nausea, vomiting, and moderate diarrhea have also been reported following orally administered OMNIPAQUE, but much less frequently. For CT examinations using dilute oral plus intravenous contrast medium, adverse events are more likely to be associated with the intravenous injection than the hypotonic oral solution. It should be noted that serious or anaphylactoid reactions that may occur with intravascular iodinated media are possible following administration by other routes. Adults In controlled clinical trials involving 54 adult patients for oral pass-thru examination of the gastrointestinal tract using OMNIPAQUE 350, the following adverse reactions were reported: diarrhea (42%), nausea (15%), vomiting (11%), abdominal pain (7%), flatulence (2%), and headache (2%). In controlled clinical studies involving 44 adult patients for dilute oral plus intravenous CT examination of the gastrointestinal tract using OMNIPAQUE 300, adverse reactions were limited to a single report of vomiting (2%). Children In controlled clinical studies involving 58 pediatric patients for examination of the gastrointestinal tract at a concentration of 300 mgI/mL, the following adverse reactions were reported: diarrhea (36%), vomiting (9%), nausea (5%), fever (5%), hypotension (2%), abdominal pain (2%), and urticaria (2%). In clinical studies an increased frequency and severity of diarrhea was noted with an increase in the administered concentration and dose of the radiocontrast agent. In controlled clinical studies involving 69 pediatric patients for dilute oral plus intravenous CT examination of the gastrointestinal tract using OMNIPAQUE 300, adverse reactions were limited to a single report of vomiting (1.4%). Dosage and Administration Adults The recommended dosage of undiluted OMNIPAQUE 350 at a concentration of 350 mgI/mL for oral pass-thru examination of the gastrointestinal tract in adults is 50 mL to 100 mL depending on the nature of the examination and the size of the patient. The recommended oral dosage of OMNIPAQUE diluted to concentrations of 6 mgI/mL to 9 mgI/mL for contrast enhanced computed tomography of the abdomen in adults is 500 mL to 1000 mL. Smaller administered volumes are needed as the concentration of the final solution is increased (see Table below). In conjunction with dilute oral administration, the recommended dosage of OMNIPAQUE 300 administered intravenously is 100 mL to 150 mL. The oral dose is administered about 20 to 40 minutes prior to the intravenous dose and image acquisition. Children The dosage of undiluted OMNIPAQUE 300 at a concentration of 300 mgI/mL, is dependent on the nature of the examination and the size of the patient. Based on clinical experience, it is recommended that OMNIPAQUE 180 (available in single use vials), be used in children less than 3 months of age. OMNIPAQUE 300 may be used in children 3 months of age and older. The following dosage guidelines are recommended: Age Volume of OMNIPAQUE Less than 3 months 5 — 30 mL Three months to 3 years Up to 60 mL Four years to 10 years Up to 80 mL Greater than 10 years Up to 100 mL When given rectally, larger volumes may be used. The recommended oral dosage of OMNIPAQUE diluted to concentrations of 9 mgI/mL to 21 mgI/mL for contrast enhanced computed tomography of the abdomen in children is 180 mL to 750 mL. Smaller administered volumes are needed as the concentration of the final solution is increased (see Table below). The total oral dose in grams of iodine should generally not exceed 5 gI for children under 3 years of age and 10 gI for children from 3 to 18 years of age. The oral dosage may be given all at once or over a period of 30 to 45 minutes if there is difficulty in consuming the required volume. In conjunction with dilute oral administration the recommended dosage of OMNIPAQUE 300 is 2.0 mL/kg when administered intravenously with a range of 1.0 mL/kg to 2.0 mL/kg. Dosage for infants and children should be administered in proportion to age and body weight. The total intravenously administered dose should not exceed 3 mL/kg. The oral dose is administered about 30 to 60 minutes prior to the intravenous dose and image acquisition. OMNIPAQUE may be diluted with water or beverage as follows: Add To Stock Concentration of OMNIPAQUE (mgI/mL) Volume (mL) Water, Carbonated Beverage, Milk, or Juice (mL) 300 20 980 350 17 983 300 30 970 350 26 974 300 40 960 350 35 965 300 50 950 350 43 957 300 60 940 350 52 948 300 70 930 350 60 940 Dilutions of OMNIPAQUE should be prepared just prior to use and any unused portion discarded after the procedure.

Launch Date

5.04403198E11
Diagnostic
OMNIPAQUE 300

Approved Use

—Intrathecal OMNIPAQUE 300 is indicated for intrathecal administration in adults including myelography (lumbar, thoracic, cervical, total columnar) and in contrast enhancement for computerized tomography (myelography, cisternography, ventriculography)., INDICATIONS AND USAGE, GENERAL—Intravascular OMNIPAQUE 350 is indicated in adults for angiocardiography (ventriculography, selective coronary arteriography), aortography including studies of the aortic root, aortic arch, ascending aorta, abdominal aorta and its branches, contrast enhancement for computed tomographic head and body imaging, intravenous digital subtraction angiography of the head, neck, abdominal, renal and peripheral vessels, peripheral arteriography, and excretory urography. OMNIPAQUE 350 is indicated in children for angiocardiography (ventriculography, pulmonary arteriography, and venography; studies of the collateral arteries and aortography, including the aortic root, aortic arch, ascending and descending aorta). OMNIPAQUE 300 is indicated in adults for aortography including studies of the aortic arch, abdominal aorta and its branches, contrast enhancement for computed tomographic head and body imaging, cerebral arteriography, peripheral venography (phlebography), and excretory urography. OMNIPAQUE 300 is indicated in children for angiocardiography (ventriculography), excretory urography, and contrast enhancement for computed tomographic head imaging., INDIVIDUAL INDICATIONS AND USAGE, INDICATIONS AND USAGE, GENERAL—Oral/Body Cavity Use OMNIPAQUE 300 and OMNIPAQUE 350 have osmolalities from approximately 1.6 to 3.0 times that of plasma (285 mOsm/kg water) and are hypertonic under conditions of use. Adults OMNIPAQUE 350 is indicated in adults for arthrography and oral pass-thru examination of the gastrointestinal tract. OMNIPAQUE 300 is indicated in adults for arthrography and hysterosalpingography. OMNIPAQUE diluted to concentrations from 6 mgI/mL to 9 mgI/mL administered orally in conjunction with OMNIPAQUE 300 at a concentration of 300 mgI/mL administered intravenously is indicated in adults for contrast enhanced computed tomography of the abdomen. Children OMNIPAQUE 300 is indicated in children for examination of the gastrointestinal tract. OMNIPAQUE diluted to concentrations from 50 mgI/mL to 100 mgI/mL is indicated in children for voiding cystourethrography. OMNIPAQUE diluted to concentrations from 9 mgI/mL to 21 mgI/mL administered orally in conjunction with OMNIPAQUE 300 at a concentration of 300 mgI/mL administered intravenously are indicated in children for use in contrast enhanced computed tomography of the abdomen., INDIVIDUAL INDICATIONS AND USAGE Oral Use Adults OMNIPAQUE 350 at a concentration of 350 mgI/mL is indicated in adults for use in oral pass-thru examination of the gastrointestinal tract. OMNIPAQUE diluted to concentrations from 6 mgI/mL to 9 mgI/mL administered orally in conjunction with OMNIPAQUE 300 at a concentration of 300 mgI/mL administered intravenously are indicated in adults for use in contrast enhanced computed tomography of the abdomen. Dilute oral plus intravenous OMNIPAQUE may be useful when unenhanced imaging does not provide sufficient delineation between normal loops of the bowel and adjacent organs or areas of suspected pathology. Children OMNIPAQUE 300 at a concentration of 300 mgI/mL administered orally or rectally is indicated in children for use in examination of the gastrointestinal tract. OMNIPAQUE diluted to concentrations from 9 mgI/mL to 21 mgI/mL administered orally in conjunction with OMNIPAQUE 300 at a concentration of 300 mgI/mL administered intravenously are indicated in children for use in contrast enhanced computed tomography of the abdomen. Precautions See PRECAUTIONS—General. Adverse Reactions Oral administration of OMNIPAQUE is most often associated with mild, transient diarrhea especially when high concentrations and large volumes are administered. Nausea, vomiting, and moderate diarrhea have also been reported following orally administered OMNIPAQUE, but much less frequently. For CT examinations using dilute oral plus intravenous contrast medium, adverse events are more likely to be associated with the intravenous injection than the hypotonic oral solution. It should be noted that serious or anaphylactoid reactions that may occur with intravascular iodinated media are possible following administration by other routes. Adults In controlled clinical trials involving 54 adult patients for oral pass-thru examination of the gastrointestinal tract using OMNIPAQUE 350, the following adverse reactions were reported: diarrhea (42%), nausea (15%), vomiting (11%), abdominal pain (7%), flatulence (2%), and headache (2%). In controlled clinical studies involving 44 adult patients for dilute oral plus intravenous CT examination of the gastrointestinal tract using OMNIPAQUE 300, adverse reactions were limited to a single report of vomiting (2%). Children In controlled clinical studies involving 58 pediatric patients for examination of the gastrointestinal tract at a concentration of 300 mgI/mL, the following adverse reactions were reported: diarrhea (36%), vomiting (9%), nausea (5%), fever (5%), hypotension (2%), abdominal pain (2%), and urticaria (2%). In clinical studies an increased frequency and severity of diarrhea was noted with an increase in the administered concentration and dose of the radiocontrast agent. In controlled clinical studies involving 69 pediatric patients for dilute oral plus intravenous CT examination of the gastrointestinal tract using OMNIPAQUE 300, adverse reactions were limited to a single report of vomiting (1.4%). Dosage and Administration Adults The recommended dosage of undiluted OMNIPAQUE 350 at a concentration of 350 mgI/mL for oral pass-thru examination of the gastrointestinal tract in adults is 50 mL to 100 mL depending on the nature of the examination and the size of the patient. The recommended oral dosage of OMNIPAQUE diluted to concentrations of 6 mgI/mL to 9 mgI/mL for contrast enhanced computed tomography of the abdomen in adults is 500 mL to 1000 mL. Smaller administered volumes are needed as the concentration of the final solution is increased (see Table below). In conjunction with dilute oral administration, the recommended dosage of OMNIPAQUE 300 administered intravenously is 100 mL to 150 mL. The oral dose is administered about 20 to 40 minutes prior to the intravenous dose and image acquisition. Children The dosage of undiluted OMNIPAQUE 300 at a concentration of 300 mgI/mL, is dependent on the nature of the examination and the size of the patient. Based on clinical experience, it is recommended that OMNIPAQUE 180 (available in single use vials), be used in children less than 3 months of age. OMNIPAQUE 300 may be used in children 3 months of age and older. The following dosage guidelines are recommended: Age Volume of OMNIPAQUE Less than 3 months 5 — 30 mL Three months to 3 years Up to 60 mL Four years to 10 years Up to 80 mL Greater than 10 years Up to 100 mL When given rectally, larger volumes may be used. The recommended oral dosage of OMNIPAQUE diluted to concentrations of 9 mgI/mL to 21 mgI/mL for contrast enhanced computed tomography of the abdomen in children is 180 mL to 750 mL. Smaller administered volumes are needed as the concentration of the final solution is increased (see Table below). The total oral dose in grams of iodine should generally not exceed 5 gI for children under 3 years of age and 10 gI for children from 3 to 18 years of age. The oral dosage may be given all at once or over a period of 30 to 45 minutes if there is difficulty in consuming the required volume. In conjunction with dilute oral administration the recommended dosage of OMNIPAQUE 300 is 2.0 mL/kg when administered intravenously with a range of 1.0 mL/kg to 2.0 mL/kg. Dosage for infants and children should be administered in proportion to age and body weight. The total intravenously administered dose should not exceed 3 mL/kg. The oral dose is administered about 30 to 60 minutes prior to the intravenous dose and image acquisition. OMNIPAQUE may be diluted with water or beverage as follows: Add To Stock Concentration of OMNIPAQUE (mgI/mL) Volume (mL) Water, Carbonated Beverage, Milk, or Juice (mL) 300 20 980 350 17 983 300 30 970 350 26 974 300 40 960 350 35 965 300 50 950 350 43 957 300 60 940 350 52 948 300 70 930 350 60 940 Dilutions of OMNIPAQUE should be prepared just prior to use and any unused portion discarded after the procedure.

Launch Date

5.04403198E11
Diagnostic
OMNIPAQUE 300

Approved Use

—Intrathecal OMNIPAQUE 300 is indicated for intrathecal administration in adults including myelography (lumbar, thoracic, cervical, total columnar) and in contrast enhancement for computerized tomography (myelography, cisternography, ventriculography)., INDICATIONS AND USAGE, GENERAL—Intravascular OMNIPAQUE 350 is indicated in adults for angiocardiography (ventriculography, selective coronary arteriography), aortography including studies of the aortic root, aortic arch, ascending aorta, abdominal aorta and its branches, contrast enhancement for computed tomographic head and body imaging, intravenous digital subtraction angiography of the head, neck, abdominal, renal and peripheral vessels, peripheral arteriography, and excretory urography. OMNIPAQUE 350 is indicated in children for angiocardiography (ventriculography, pulmonary arteriography, and venography; studies of the collateral arteries and aortography, including the aortic root, aortic arch, ascending and descending aorta). OMNIPAQUE 300 is indicated in adults for aortography including studies of the aortic arch, abdominal aorta and its branches, contrast enhancement for computed tomographic head and body imaging, cerebral arteriography, peripheral venography (phlebography), and excretory urography. OMNIPAQUE 300 is indicated in children for angiocardiography (ventriculography), excretory urography, and contrast enhancement for computed tomographic head imaging., INDIVIDUAL INDICATIONS AND USAGE, INDICATIONS AND USAGE, GENERAL—Oral/Body Cavity Use OMNIPAQUE 300 and OMNIPAQUE 350 have osmolalities from approximately 1.6 to 3.0 times that of plasma (285 mOsm/kg water) and are hypertonic under conditions of use. Adults OMNIPAQUE 350 is indicated in adults for arthrography and oral pass-thru examination of the gastrointestinal tract. OMNIPAQUE 300 is indicated in adults for arthrography and hysterosalpingography. OMNIPAQUE diluted to concentrations from 6 mgI/mL to 9 mgI/mL administered orally in conjunction with OMNIPAQUE 300 at a concentration of 300 mgI/mL administered intravenously is indicated in adults for contrast enhanced computed tomography of the abdomen. Children OMNIPAQUE 300 is indicated in children for examination of the gastrointestinal tract. OMNIPAQUE diluted to concentrations from 50 mgI/mL to 100 mgI/mL is indicated in children for voiding cystourethrography. OMNIPAQUE diluted to concentrations from 9 mgI/mL to 21 mgI/mL administered orally in conjunction with OMNIPAQUE 300 at a concentration of 300 mgI/mL administered intravenously are indicated in children for use in contrast enhanced computed tomography of the abdomen., INDIVIDUAL INDICATIONS AND USAGE Oral Use Adults OMNIPAQUE 350 at a concentration of 350 mgI/mL is indicated in adults for use in oral pass-thru examination of the gastrointestinal tract. OMNIPAQUE diluted to concentrations from 6 mgI/mL to 9 mgI/mL administered orally in conjunction with OMNIPAQUE 300 at a concentration of 300 mgI/mL administered intravenously are indicated in adults for use in contrast enhanced computed tomography of the abdomen. Dilute oral plus intravenous OMNIPAQUE may be useful when unenhanced imaging does not provide sufficient delineation between normal loops of the bowel and adjacent organs or areas of suspected pathology. Children OMNIPAQUE 300 at a concentration of 300 mgI/mL administered orally or rectally is indicated in children for use in examination of the gastrointestinal tract. OMNIPAQUE diluted to concentrations from 9 mgI/mL to 21 mgI/mL administered orally in conjunction with OMNIPAQUE 300 at a concentration of 300 mgI/mL administered intravenously are indicated in children for use in contrast enhanced computed tomography of the abdomen. Precautions See PRECAUTIONS—General. Adverse Reactions Oral administration of OMNIPAQUE is most often associated with mild, transient diarrhea especially when high concentrations and large volumes are administered. Nausea, vomiting, and moderate diarrhea have also been reported following orally administered OMNIPAQUE, but much less frequently. For CT examinations using dilute oral plus intravenous contrast medium, adverse events are more likely to be associated with the intravenous injection than the hypotonic oral solution. It should be noted that serious or anaphylactoid reactions that may occur with intravascular iodinated media are possible following administration by other routes. Adults In controlled clinical trials involving 54 adult patients for oral pass-thru examination of the gastrointestinal tract using OMNIPAQUE 350, the following adverse reactions were reported: diarrhea (42%), nausea (15%), vomiting (11%), abdominal pain (7%), flatulence (2%), and headache (2%). In controlled clinical studies involving 44 adult patients for dilute oral plus intravenous CT examination of the gastrointestinal tract using OMNIPAQUE 300, adverse reactions were limited to a single report of vomiting (2%). Children In controlled clinical studies involving 58 pediatric patients for examination of the gastrointestinal tract at a concentration of 300 mgI/mL, the following adverse reactions were reported: diarrhea (36%), vomiting (9%), nausea (5%), fever (5%), hypotension (2%), abdominal pain (2%), and urticaria (2%). In clinical studies an increased frequency and severity of diarrhea was noted with an increase in the administered concentration and dose of the radiocontrast agent. In controlled clinical studies involving 69 pediatric patients for dilute oral plus intravenous CT examination of the gastrointestinal tract using OMNIPAQUE 300, adverse reactions were limited to a single report of vomiting (1.4%). Dosage and Administration Adults The recommended dosage of undiluted OMNIPAQUE 350 at a concentration of 350 mgI/mL for oral pass-thru examination of the gastrointestinal tract in adults is 50 mL to 100 mL depending on the nature of the examination and the size of the patient. The recommended oral dosage of OMNIPAQUE diluted to concentrations of 6 mgI/mL to 9 mgI/mL for contrast enhanced computed tomography of the abdomen in adults is 500 mL to 1000 mL. Smaller administered volumes are needed as the concentration of the final solution is increased (see Table below). In conjunction with dilute oral administration, the recommended dosage of OMNIPAQUE 300 administered intravenously is 100 mL to 150 mL. The oral dose is administered about 20 to 40 minutes prior to the intravenous dose and image acquisition. Children The dosage of undiluted OMNIPAQUE 300 at a concentration of 300 mgI/mL, is dependent on the nature of the examination and the size of the patient. Based on clinical experience, it is recommended that OMNIPAQUE 180 (available in single use vials), be used in children less than 3 months of age. OMNIPAQUE 300 may be used in children 3 months of age and older. The following dosage guidelines are recommended: Age Volume of OMNIPAQUE Less than 3 months 5 — 30 mL Three months to 3 years Up to 60 mL Four years to 10 years Up to 80 mL Greater than 10 years Up to 100 mL When given rectally, larger volumes may be used. The recommended oral dosage of OMNIPAQUE diluted to concentrations of 9 mgI/mL to 21 mgI/mL for contrast enhanced computed tomography of the abdomen in children is 180 mL to 750 mL. Smaller administered volumes are needed as the concentration of the final solution is increased (see Table below). The total oral dose in grams of iodine should generally not exceed 5 gI for children under 3 years of age and 10 gI for children from 3 to 18 years of age. The oral dosage may be given all at once or over a period of 30 to 45 minutes if there is difficulty in consuming the required volume. In conjunction with dilute oral administration the recommended dosage of OMNIPAQUE 300 is 2.0 mL/kg when administered intravenously with a range of 1.0 mL/kg to 2.0 mL/kg. Dosage for infants and children should be administered in proportion to age and body weight. The total intravenously administered dose should not exceed 3 mL/kg. The oral dose is administered about 30 to 60 minutes prior to the intravenous dose and image acquisition. OMNIPAQUE may be diluted with water or beverage as follows: Add To Stock Concentration of OMNIPAQUE (mgI/mL) Volume (mL) Water, Carbonated Beverage, Milk, or Juice (mL) 300 20 980 350 17 983 300 30 970 350 26 974 300 40 960 350 35 965 300 50 950 350 43 957 300 60 940 350 52 948 300 70 930 350 60 940 Dilutions of OMNIPAQUE should be prepared just prior to use and any unused portion discarded after the procedure.

Launch Date

5.04403198E11
Diagnostic
OMNIPAQUE 300

Approved Use

—Intrathecal OMNIPAQUE 300 is indicated for intrathecal administration in adults including myelography (lumbar, thoracic, cervical, total columnar) and in contrast enhancement for computerized tomography (myelography, cisternography, ventriculography)., INDICATIONS AND USAGE, GENERAL—Intravascular OMNIPAQUE 350 is indicated in adults for angiocardiography (ventriculography, selective coronary arteriography), aortography including studies of the aortic root, aortic arch, ascending aorta, abdominal aorta and its branches, contrast enhancement for computed tomographic head and body imaging, intravenous digital subtraction angiography of the head, neck, abdominal, renal and peripheral vessels, peripheral arteriography, and excretory urography. OMNIPAQUE 350 is indicated in children for angiocardiography (ventriculography, pulmonary arteriography, and venography; studies of the collateral arteries and aortography, including the aortic root, aortic arch, ascending and descending aorta). OMNIPAQUE 300 is indicated in adults for aortography including studies of the aortic arch, abdominal aorta and its branches, contrast enhancement for computed tomographic head and body imaging, cerebral arteriography, peripheral venography (phlebography), and excretory urography. OMNIPAQUE 300 is indicated in children for angiocardiography (ventriculography), excretory urography, and contrast enhancement for computed tomographic head imaging., INDIVIDUAL INDICATIONS AND USAGE, INDICATIONS AND USAGE, GENERAL—Oral/Body Cavity Use OMNIPAQUE 300 and OMNIPAQUE 350 have osmolalities from approximately 1.6 to 3.0 times that of plasma (285 mOsm/kg water) and are hypertonic under conditions of use. Adults OMNIPAQUE 350 is indicated in adults for arthrography and oral pass-thru examination of the gastrointestinal tract. OMNIPAQUE 300 is indicated in adults for arthrography and hysterosalpingography. OMNIPAQUE diluted to concentrations from 6 mgI/mL to 9 mgI/mL administered orally in conjunction with OMNIPAQUE 300 at a concentration of 300 mgI/mL administered intravenously is indicated in adults for contrast enhanced computed tomography of the abdomen. Children OMNIPAQUE 300 is indicated in children for examination of the gastrointestinal tract. OMNIPAQUE diluted to concentrations from 50 mgI/mL to 100 mgI/mL is indicated in children for voiding cystourethrography. OMNIPAQUE diluted to concentrations from 9 mgI/mL to 21 mgI/mL administered orally in conjunction with OMNIPAQUE 300 at a concentration of 300 mgI/mL administered intravenously are indicated in children for use in contrast enhanced computed tomography of the abdomen., INDIVIDUAL INDICATIONS AND USAGE Oral Use Adults OMNIPAQUE 350 at a concentration of 350 mgI/mL is indicated in adults for use in oral pass-thru examination of the gastrointestinal tract. OMNIPAQUE diluted to concentrations from 6 mgI/mL to 9 mgI/mL administered orally in conjunction with OMNIPAQUE 300 at a concentration of 300 mgI/mL administered intravenously are indicated in adults for use in contrast enhanced computed tomography of the abdomen. Dilute oral plus intravenous OMNIPAQUE may be useful when unenhanced imaging does not provide sufficient delineation between normal loops of the bowel and adjacent organs or areas of suspected pathology. Children OMNIPAQUE 300 at a concentration of 300 mgI/mL administered orally or rectally is indicated in children for use in examination of the gastrointestinal tract. OMNIPAQUE diluted to concentrations from 9 mgI/mL to 21 mgI/mL administered orally in conjunction with OMNIPAQUE 300 at a concentration of 300 mgI/mL administered intravenously are indicated in children for use in contrast enhanced computed tomography of the abdomen. Precautions See PRECAUTIONS—General. Adverse Reactions Oral administration of OMNIPAQUE is most often associated with mild, transient diarrhea especially when high concentrations and large volumes are administered. Nausea, vomiting, and moderate diarrhea have also been reported following orally administered OMNIPAQUE, but much less frequently. For CT examinations using dilute oral plus intravenous contrast medium, adverse events are more likely to be associated with the intravenous injection than the hypotonic oral solution. It should be noted that serious or anaphylactoid reactions that may occur with intravascular iodinated media are possible following administration by other routes. Adults In controlled clinical trials involving 54 adult patients for oral pass-thru examination of the gastrointestinal tract using OMNIPAQUE 350, the following adverse reactions were reported: diarrhea (42%), nausea (15%), vomiting (11%), abdominal pain (7%), flatulence (2%), and headache (2%). In controlled clinical studies involving 44 adult patients for dilute oral plus intravenous CT examination of the gastrointestinal tract using OMNIPAQUE 300, adverse reactions were limited to a single report of vomiting (2%). Children In controlled clinical studies involving 58 pediatric patients for examination of the gastrointestinal tract at a concentration of 300 mgI/mL, the following adverse reactions were reported: diarrhea (36%), vomiting (9%), nausea (5%), fever (5%), hypotension (2%), abdominal pain (2%), and urticaria (2%). In clinical studies an increased frequency and severity of diarrhea was noted with an increase in the administered concentration and dose of the radiocontrast agent. In controlled clinical studies involving 69 pediatric patients for dilute oral plus intravenous CT examination of the gastrointestinal tract using OMNIPAQUE 300, adverse reactions were limited to a single report of vomiting (1.4%). Dosage and Administration Adults The recommended dosage of undiluted OMNIPAQUE 350 at a concentration of 350 mgI/mL for oral pass-thru examination of the gastrointestinal tract in adults is 50 mL to 100 mL depending on the nature of the examination and the size of the patient. The recommended oral dosage of OMNIPAQUE diluted to concentrations of 6 mgI/mL to 9 mgI/mL for contrast enhanced computed tomography of the abdomen in adults is 500 mL to 1000 mL. Smaller administered volumes are needed as the concentration of the final solution is increased (see Table below). In conjunction with dilute oral administration, the recommended dosage of OMNIPAQUE 300 administered intravenously is 100 mL to 150 mL. The oral dose is administered about 20 to 40 minutes prior to the intravenous dose and image acquisition. Children The dosage of undiluted OMNIPAQUE 300 at a concentration of 300 mgI/mL, is dependent on the nature of the examination and the size of the patient. Based on clinical experience, it is recommended that OMNIPAQUE 180 (available in single use vials), be used in children less than 3 months of age. OMNIPAQUE 300 may be used in children 3 months of age and older. The following dosage guidelines are recommended: Age Volume of OMNIPAQUE Less than 3 months 5 — 30 mL Three months to 3 years Up to 60 mL Four years to 10 years Up to 80 mL Greater than 10 years Up to 100 mL When given rectally, larger volumes may be used. The recommended oral dosage of OMNIPAQUE diluted to concentrations of 9 mgI/mL to 21 mgI/mL for contrast enhanced computed tomography of the abdomen in children is 180 mL to 750 mL. Smaller administered volumes are needed as the concentration of the final solution is increased (see Table below). The total oral dose in grams of iodine should generally not exceed 5 gI for children under 3 years of age and 10 gI for children from 3 to 18 years of age. The oral dosage may be given all at once or over a period of 30 to 45 minutes if there is difficulty in consuming the required volume. In conjunction with dilute oral administration the recommended dosage of OMNIPAQUE 300 is 2.0 mL/kg when administered intravenously with a range of 1.0 mL/kg to 2.0 mL/kg. Dosage for infants and children should be administered in proportion to age and body weight. The total intravenously administered dose should not exceed 3 mL/kg. The oral dose is administered about 30 to 60 minutes prior to the intravenous dose and image acquisition. OMNIPAQUE may be diluted with water or beverage as follows: Add To Stock Concentration of OMNIPAQUE (mgI/mL) Volume (mL) Water, Carbonated Beverage, Milk, or Juice (mL) 300 20 980 350 17 983 300 30 970 350 26 974 300 40 960 350 35 965 300 50 950 350 43 957 300 60 940 350 52 948 300 70 930 350 60 940 Dilutions of OMNIPAQUE should be prepared just prior to use and any unused portion discarded after the procedure.

Launch Date

5.04403198E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
16.395 μg/mL
647.11 mg single, subcutaneous
dose: 647.11 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
IOHEXOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
6365.609 μg × min/mL
647.11 mg single, subcutaneous
dose: 647.11 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
IOHEXOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
139.132 min
647.11 mg single, subcutaneous
dose: 647.11 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
IOHEXOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
119 min
269.63 mg/kg single, intravenous
dose: 269.63 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
IOHEXOL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
20 min
IOHEXOL blood
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
100%
IOHEXOL blood
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1510 mg/kg 1 times / day single, intraarterial
Highest studied dose
Dose: 1510 mg/kg, 1 times / day
Route: intraarterial
Route: single
Dose: 1510 mg/kg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: coronary artery disease
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
not significant
PubMed

PubMed

TitleDatePubMed
Contrast-medium-induced nephrotoxicity: are all answers in for acetylcysteine?
2001
Use of spiral CT and the contrast medium iohexol to determine in one session aortorenal morphology and the relative glomerular filtration rate of each kidney.
2001
Hepatic and vascular enhancement at dual-phase helical CT: comparison of Iobitridol 300 and Iohexol 300 in a prospective randomized study.
2001
One-step subcellular fractionation of rat liver tissue using a Nycodenz density gradient prepared by freezing-thawing and two-dimensional sodium dodecyl sulfate electrophoresis profiles of the main fraction of organelles.
2001 Aug
Plasma clearance of iodine contrast media as a measure of glomerular filtration rate in critically ill patients.
2001 Aug
No evidence of accelerated loss of kidney function in living kidney donors: results from a cross-sectional follow-up.
2001 Aug 15
Is contrast-related vasodilatation after intra-coronary iodixanol and iopromide in vivo endothelium-dependent?
2001 Dec
Sodium and water homeostasis in children with shigellosis.
2001 Dec
Effects of radiographic contrast media on pulmonary vascular resistance of normoxic and chronically hypoxic pulmonary hypertensive rats.
2001 Dec
Radiographic contrast media induced nephropathy: experimental observations and the protective effect of calcium channel blockers.
2001 Dec
Stabilization of the hydrophilic sphere of non-ionic monomers: are all protected in a similar way?
2001 Dec
[Mesenteric panniculitis].
2001 Jul
Glucose alters the susceptibility of mesangial cells to contrast media.
2001 Jul
[Diagnosis of bilateral pulmonary thrombosis by electron radiation imaging and magnetic resonance imaging].
2001 Jul-Aug
Enhanced CT in the diagnosis of acute appendicitis to evaluate the severity of disease: comparison of CT findings and histological diagnosis.
2001 Jul-Aug
Renal effects of cardiac angiography with different low-osmolar contrast media.
2001 May-Jul
Comparison of the effects of radiographic contrast media on dehydration and filterability of red blood cells from donors homozygous for hemoglobin A or hemoglobin S.
2001 Nov
Proteinuria and plasma total homocysteine levels in chronic renal disease patients with a normal range serum creatinine: critical impact of true glomerular filtration rate.
2001 Nov
The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study.
2001 Nov
[Thyroid function after iodine-containing contrast agent administration in coronary angiography: a prospective study of euthyroid patients].
2001 Oct
[Impact of different iodine concentrations on abdominal enhancement in biphasic multislice helical CT (MS-CT)].
2001 Oct
Comparative study between gadobenate dimeglumine and gadobutrol in rats with brain ischemia: evaluation of somatosensory evoked potentials.
2001 Oct
Delayed exanthema to nonionic contrast medium.
2001 Oct
Investigation of aortocoronary artery bypass grafts by multislice spiral computed tomography with electrocardiographic-gated image reconstruction.
2001 Oct 1
Clinical application of plasma clearance of iohexol on feline patients.
2001 Sep
[Severe reactions to iodinated contrast agents: is anaphylaxis responsible?].
2001 Sep
Measurement of single kidney contrast media clearance by multiphasic spiral computed tomography: preliminary results.
2001 Sep
Changes in endothelial, leucocyte and platelet markers following contrast medium injection during angiography in patients with peripheral artery disease.
2001 Sep
CT pulmonary angiography with a macromolecular contrast medium: a comparative study versus iobitridol in rabbits.
2001 Sep
Experiences with iohexol and iodixanol during cardioangiography in an unselected patient population.
2001 Sep-Oct
Contrast media as markers of GFR.
2002 Feb
Is contrast as bad as we think? Renal function after angiographic embolization of injured patients.
2002 Feb
Apolipoprotein A-IV serum concentrations are elevated in patients with mild and moderate renal failure.
2002 Feb
Cardiac arrest after administration of Omnipaque radiocontrast medium during endoluminal repair of abdominal aortic aneurysm.
2002 Jan
Comments on F. Stacul: Current iodinated contrast media.
2002 Jan
Effect of arthrocentesis on TMJ disturbance of mouth closure with loud clicking: a preliminary study.
2002 Jan
Systemic platelet effects of contrast media: implications for cardiologic research and clinical practice.
2002 Jan
Investigations into the environmental fate and effects of iopromide (ultravist), a widely used iodinated X-ray contrast medium.
2002 Jan
Comparison of intraarterial and IV gadolinium-enhanced MR angiography with digital subtraction angiography for the detection of renal artery stenosis in pigs.
2002 Jan
Contrast media clearance in a single kidney measured on multiphasic helical CT: results in 50 patients without acute renal disorder.
2002 Jan
CT of duodenal angiomyolipoma [corrected].
2002 Jan
Acute cardiac tolerance of current contrast media and the new taxane protaxel using iopromide as carrier during porcine coronary angiography and stenting.
2002 Jan
Contrast media increase vascular endothelial permeability by inhibiting nitric-oxide production.
2002 Jan
Transforaminal epidural steroid injections in lumbosacral radiculopathy: a prospective randomized study.
2002 Jan 1
Optimization of contrast agent volume for helical CT in the diagnostic assessment of patients with severe and multiple injuries.
2002 Jan-Feb
Optimal scan delay in spiral CT for the diagnosis of acute pulmonary embolism.
2002 Jan-Feb
Changes in the fibrinolytic system during angiography with ionic and with nonionic contrast media.
2002 Mar
[A differentiated approach to the diagnosis of pulmonary embolism and deep venous thrombosis using multi-slice CT].
2002 Mar
Comparative cytotoxicity of low-osmolar nonionic and high-osmolar ionic contrast media to dog gallbladder epithelial cells.
2002 Mar
Fatal cardiac arrest during infusion of nonionic contrast media in a patient with essential thrombocythemia.
2002 Mar
Patents

Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: OMNIPAQUE is available in different concentrations: 70, 140, 180, 210, 240, 300 and 350 mgI/ml.
Intrathecal: OMNIPAQUE 240 (concentration 240 mgI/mL) - the usual recommended total doses for use in lumbar, thoracic, cervical, and total columnar myelography in adults are 1.2 gI to 3.06 gI (6-12.5 ml). Intravascular: The recommended single injection volume of OMNIPAQUE 350 (concentration 350 mgI/mL) for angiocardiographic procedures is 40 mL with a range of 30 mL to 60 mL. Oral: The recommended dosage of undiluted OMNIPAQUE 350 (concentration of 350 mgI/mL) for oral pass-thru examination of the gastrointestinal tract in adults is 50 mL to 100 mL depending on the nature of the examination and the size of the patient.
Route of Administration: Other
In Vitro Use Guide
Curator's Comment:: Iohexol increases the clotting time. http://www.ncbi.nlm.nih.gov/pubmed/2745021
Diffusion of iohexol (300 and 240 mgI/ml) was studied in the cerebrospinal fluid (CSF). Test tubes containing CSF were kept in a waterbath at 37 degrees C. Contrast medium was injected along the wall into the tubes, and diffusion of contrast media in the tubes was followed with repeated computed tomography for 5 h. The contents of the tubes were then mixed by shaking, and the tubes were scanned immediately and 8 h later.
Name Type Language
IOHEXOL
EP   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
USAN   INN  
Official Name English
IOHEXOL [INN]
Common Name English
NSC-759636
Code English
WIN-39424
Code English
1,3-BENZENEDICARBOXAMIDE, 5-(ACETYL(2,3-DIHYDROXYPROPYL)AMINO)-N,N'-BIS(2,3-DIHYDROXYPROPYL)-2,4,6-TRIIODO
Common Name English
N,N'-BIS(2,3-DIHYDROXYPROPYL)-5-(N-(2,3-DIHYDROXYPROPYL)ACETAMIDO)-2,4,6-TRIIODOISOPHTHALAMIDE
Systematic Name English
IOHEXOL [USAN]
Common Name English
IOHEXOL [ORANGE BOOK]
Common Name English
WIN 39424
Code English
IOHEXOLUM [WHO-IP LATIN]
Common Name English
IOHEXOL [JAN]
Common Name English
IOHEXOL [EP MONOGRAPH]
Common Name English
IOHEXOL [MART.]
Common Name English
IOHEXOL [USP-RS]
Common Name English
IOHEXOL [VANDF]
Common Name English
ORALTAG
Brand Name English
OMNIPAQUE
Brand Name English
IOHEXOL [WHO-DD]
Common Name English
IOHEXOL [WHO-IP]
Common Name English
IOHEXOL [EP]
Common Name English
IOHEXOL [USP MONOGRAPH]
Common Name English
IOHEXOL [MI]
Common Name English
Classification Tree Code System Code
NDF-RT N0000010258
Created by admin on Fri Jun 25 21:03:55 UTC 2021 , Edited by admin on Fri Jun 25 21:03:55 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 14.2
Created by admin on Fri Jun 25 21:03:55 UTC 2021 , Edited by admin on Fri Jun 25 21:03:55 UTC 2021
WHO-VATC QV08AB02
Created by admin on Fri Jun 25 21:03:55 UTC 2021 , Edited by admin on Fri Jun 25 21:03:55 UTC 2021
NCI_THESAURUS C28500
Created by admin on Fri Jun 25 21:03:55 UTC 2021 , Edited by admin on Fri Jun 25 21:03:55 UTC 2021
NDF-RT N0000180185
Created by admin on Fri Jun 25 21:03:55 UTC 2021 , Edited by admin on Fri Jun 25 21:03:55 UTC 2021
WHO-ATC V08AB02
Created by admin on Fri Jun 25 21:03:55 UTC 2021 , Edited by admin on Fri Jun 25 21:03:55 UTC 2021
Code System Code Type Description
MESH
D007472
Created by admin on Fri Jun 25 21:03:55 UTC 2021 , Edited by admin on Fri Jun 25 21:03:55 UTC 2021
PRIMARY
PUBCHEM
3730
Created by admin on Fri Jun 25 21:03:55 UTC 2021 , Edited by admin on Fri Jun 25 21:03:55 UTC 2021
PRIMARY
MERCK INDEX
M6365
Created by admin on Fri Jun 25 21:03:55 UTC 2021 , Edited by admin on Fri Jun 25 21:03:55 UTC 2021
PRIMARY Merck Index
NCI_THESAURUS
C65939
Created by admin on Fri Jun 25 21:03:55 UTC 2021 , Edited by admin on Fri Jun 25 21:03:55 UTC 2021
PRIMARY
RXCUI
5956
Created by admin on Fri Jun 25 21:03:55 UTC 2021 , Edited by admin on Fri Jun 25 21:03:55 UTC 2021
PRIMARY RxNorm
USP_CATALOG
1344600
Created by admin on Fri Jun 25 21:03:55 UTC 2021 , Edited by admin on Fri Jun 25 21:03:55 UTC 2021
PRIMARY USP-RS
FDA UNII
4419T9MX03
Created by admin on Fri Jun 25 21:03:55 UTC 2021 , Edited by admin on Fri Jun 25 21:03:55 UTC 2021
PRIMARY
CAS
66108-95-0
Created by admin on Fri Jun 25 21:03:55 UTC 2021 , Edited by admin on Fri Jun 25 21:03:55 UTC 2021
PRIMARY
EVMPD
SUB08228MIG
Created by admin on Fri Jun 25 21:03:55 UTC 2021 , Edited by admin on Fri Jun 25 21:03:55 UTC 2021
PRIMARY
ECHA (EC/EINECS)
266-164-2
Created by admin on Fri Jun 25 21:03:55 UTC 2021 , Edited by admin on Fri Jun 25 21:03:55 UTC 2021
PRIMARY
EPA CompTox
66108-95-0
Created by admin on Fri Jun 25 21:03:55 UTC 2021 , Edited by admin on Fri Jun 25 21:03:55 UTC 2021
PRIMARY
WIKIPEDIA
IOHEXOL
Created by admin on Fri Jun 25 21:03:55 UTC 2021 , Edited by admin on Fri Jun 25 21:03:55 UTC 2021
PRIMARY
INN
4848
Created by admin on Fri Jun 25 21:03:55 UTC 2021 , Edited by admin on Fri Jun 25 21:03:55 UTC 2021
PRIMARY
LACTMED
Iohexol
Created by admin on Fri Jun 25 21:03:55 UTC 2021 , Edited by admin on Fri Jun 25 21:03:55 UTC 2021
PRIMARY
DRUG CENTRAL
1461
Created by admin on Fri Jun 25 21:03:55 UTC 2021 , Edited by admin on Fri Jun 25 21:03:55 UTC 2021
PRIMARY
ChEMBL
CHEMBL1200455
Created by admin on Fri Jun 25 21:03:55 UTC 2021 , Edited by admin on Fri Jun 25 21:03:55 UTC 2021
PRIMARY
DRUG BANK
DB01362
Created by admin on Fri Jun 25 21:03:55 UTC 2021 , Edited by admin on Fri Jun 25 21:03:55 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
IOHEXOL
Created by admin on Fri Jun 25 21:03:55 UTC 2021 , Edited by admin on Fri Jun 25 21:03:55 UTC 2021
PRIMARY Description: A white to greyish, amorphous powder; odourless. Solubility: Very soluble in water and methanol R. Category: Radiocontrast medium. Storage: Iohexol should be kept in a well-closed container, protected from light. Additional information: Melting range, 177-187 ?C. Definition: Iohexol contains not less than 98.5% and not more than the equivalent of 101.5% of C19H26I3N3O9, calculated with reference to the anhydrous substance.